Currently, there is a wide range of blood tests that assist in determining various diseases. But the latest invention could transform the screening procedure. A new kind of blood test utilizes a single plasma sample to estimate health. Even more, it can predict the probability of developing various diseases. According to the new feasibility study, published in the journal Nature Medicine, suggests the novel blood test. Notably, it could pretend a person’s risk of evolving a wide range of diverse diseases. Scientists have named the latest blood test as – liquid health check. The technique uses a machine learning approach to recognize the arrangement of proteins that can be tied to specific health conditions.
The liquid health check can even predict the probability of developing diseases like type 2 diabetes. Scientists from the Universities of California and Cambridge, San Francisco, have experimented with the clinical test on around 17,000 people. The outcomes have revealed that liquid health check can spot patients having a severe kidney infection, and people at-risk of getting type-2 diabetes. Even more, it can determine fat wrapped around organs in the human body. Currently, the test is in the primary phase of development. Thus it remains a bit less accurate at anticipating the threat of cardiovascular disorders, including stroke or heart attack.
Till now, the new research has tested the effectiveness of predicting 11 diverse health symptoms using three protein expression designs. SomaLogic is a pharmaceutical startup company functioning to market the latest invention. Stephen Williams, SomaLogic’s CEO, says it is notable that the structure of plasma protein alone can authentically represent such a wide variety of ordinary and significant health concerns. As per the executive, the finding is just the tip of the iceberg, as they have hundreds of tests in the queue. Even more, they expect that extensive protein scanning has the power to become a solitary source of information in case of personalized health estimations. For now, the research is in the proof-of-concept stage, and it requires further verification to adopt it for clinical use.